Dr. Reddy's Laboratories says HIV prevention news is not a material event

Dr. Reddy's Laboratories (NSE: DRREDDY) responded to a query from the National Stock Exchange of India on a news article about a US tentative approval for its injectable HIV prevention drug, it said in a filing on 04 Nov 2026. The company says the headline is correct and that the article relates to its 2 Nov 2026 press release.

What the exchange asked and what the company replied

The National Stock Exchange of India wrote to the company by e-mail dated 3 Nov 2026, seeking clarification on an article published by First Post the same day. The article was captioned "India's Dr Reddy's gets US nod for $40 generic HIV prevention shot for 120 poorer countries".

The company says the headline is correct and that the article pertains to its press release of 2 Nov 2026, titled "U.S. FDA grants tentative approval for Dr. Reddy's twice-yearly injectable lenacapavir, advancing access to HIV prevention across 120 countries outside the US." The company says the matter does not constitute a material event under Regulation 30 of the SEBI Listing Regulations.

Company answers on negotiations and impact

Asked whether negotiations were taking place, the company answered "Not applicable". It says that at this stage there is no material event or information requiring disclosure, and that it believes the article has no material impact on the company.

The company says it makes prompt disclosures when an event or information is considered material. The exchange's reference for the query is NSE/CM/Surveillance/17766. The letter is signed by K Randhir Singh, Company Secretary, Compliance Officer and Head-CSR, and is dated 4 Nov 2026.

What the clarification means for Dr. Reddy's Laboratories shareholders

The filing puts the US tentative approval and the 120-country access plan in the company's own 2 Nov 2026 press release, and the company says it is not a material event. The company's latest quarter, Q1 FY27, showed consolidated total income of ₹8,454.50 crore and net profit of ₹435.60 crore, but the filing does not link that result to this news.

Not stated: the price movement that prompted the query, the expected sales or revenue from the product, when the tentative approval could become final, and the commercial terms or partners for supplying 120 countries. The company has not announced a next dated step in this filing.

At a glance